See more : LGMS Berhad (0249.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Vincerx Pharma, Inc. (VINC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vincerx Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- NAVER Corporation (035420.KS) Income Statement Analysis – Financial Results
- Minsud Resources Corp. (MSR.V) Income Statement Analysis – Financial Results
- Standard Lithium Ltd. (0VIK.L) Income Statement Analysis – Financial Results
- CASASOLD S.p.A. (CASA.MI) Income Statement Analysis – Financial Results
- Harrys Manufacturing Inc. (WSRRF) Income Statement Analysis – Financial Results
Vincerx Pharma, Inc. (VINC)
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 915.00K | 939.00K | 340.00K | 173.00K | 173.00K |
| Gross Profit | -915.00K | -939.00K | -340.00K | -173.00K | -173.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 28.97M | 52.15M | 40.08M | 7.12M | 0.00 |
| General & Administrative | 13.64M | 18.95M | 22.58M | 3.60M | 54.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 44.95K |
| SG&A | 13.64M | 18.95M | 22.58M | 3.60M | 45.00K |
| Other Expenses | 0.00 | 1.24M | -8.00K | -8.00K | 0.00 |
| Operating Expenses | 42.61M | 71.11M | 62.66M | 10.71M | 45.00K |
| Cost & Expenses | 42.61M | 71.11M | 62.66M | 10.71M | 45.00K |
| Interest Income | 1.25M | 664.00K | 0.00 | 54.27K | 54.27K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 |
| Depreciation & Amortization | 52.00K | 939.00K | 340.00K | 5.71M | 54.00K |
| EBITDA | -42.61M | -68.67M | -62.66M | -10.71M | 9.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.61M | -73.57M | -62.66M | -10.71M | -45.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.45M | 8.21M | 23.35M | -5.91M | 0.00 |
| Income Before Tax | -40.16M | -65.37M | -39.31M | -10.72M | -45.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.21M | -23.70M | 8.00K | -54.00 |
| Net Income | -40.16M | -57.16M | -15.61M | -10.73M | -45.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
| EPS Diluted | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
| Weighted Avg Shares Out | 21.30M | 21.03M | 17.18M | 13.98M | 5.20M |
| Weighted Avg Shares Out (Dil) | 21.30M | 21.03M | 17.18M | 13.98M | 5.20M |
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943
Also Exploring Strategic Alternatives to Complement Fundraising Efforts Also Exploring Strategic Alternatives to Complement Fundraising Efforts
What Makes Vincerx Pharma (VINC) a New Buy Stock
Vincerx Pharma (VINC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates
On Monday, Vincerx Pharma VINC shared updates on its ongoing Phase 1 studies of VIP943, VIP236, and enitociclib, which aim to address various blood cancers.
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Platform technology
Vincerx Pharma Reports Second Quarter 2024 Financial Results
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024
Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade
Vincerx Pharma (VINC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC)
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate...
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and,...
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.
Source: https://incomestatements.info
Category: Stock Reports